niacinamide has been researched along with Allodynia in 10 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In addition, the effect of intrathecal injection of NAD or resveratrol on thermal hyperalgesia and mechanical allodynia was evaluated in CCI mice." | 3.80 | Spinal SIRT1 activation attenuates neuropathic pain in mice. ( Ding, W; Luo, Y; Shao, H; Xue, Q; Yu, B; Zhang, F; Zhang, H; Zhang, X; Zhu, H, 2014) |
| "Peripheral neuropathic pain induced by the chemotherapeutic cisplatin can persist for months to years after treatment." | 1.72 | HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling. ( Grace, PM; Heijnen, CJ; Junigan, JM; Kavelaars, A; Trinh, R; Zhang, J, 2022) |
| "Sorafenib treatments did not affect paw-withdrawal responses to non-noxious or to noxious mechanical stimuli." | 1.42 | A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam. ( Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, J | 1 |
| Junigan, JM | 1 |
| Trinh, R | 1 |
| Kavelaars, A | 1 |
| Heijnen, CJ | 1 |
| Grace, PM | 1 |
| Hamity, MV | 1 |
| White, SR | 1 |
| Walder, RY | 1 |
| Schmidt, MS | 1 |
| Brenner, C | 1 |
| Hammond, DL | 1 |
| Ovalle-Magallanes, B | 2 |
| Déciga-Campos, M | 2 |
| Mata, R | 2 |
| Braga, AV | 1 |
| Costa, SOAM | 1 |
| Rodrigues, FF | 1 |
| Melo, ISF | 1 |
| Morais, MI | 1 |
| Coelho, MM | 1 |
| Machado, RR | 1 |
| Shao, H | 1 |
| Xue, Q | 1 |
| Zhang, F | 1 |
| Luo, Y | 1 |
| Zhu, H | 1 |
| Zhang, X | 1 |
| Zhang, H | 1 |
| Ding, W | 1 |
| Yu, B | 1 |
| Di Cesare Mannelli, L | 1 |
| Maresca, M | 1 |
| Farina, C | 1 |
| Scherz, MW | 1 |
| Ghelardini, C | 1 |
| Negi, G | 1 |
| Kumar, A | 1 |
| Kaundal, RK | 1 |
| Gulati, A | 1 |
| Sharma, SS | 1 |
| Zhang, XF | 1 |
| Shieh, CC | 1 |
| Chapman, ML | 1 |
| Matulenko, MA | 1 |
| Hakeem, AH | 1 |
| Atkinson, RN | 1 |
| Kort, ME | 1 |
| Marron, BE | 1 |
| Joshi, S | 1 |
| Honore, P | 1 |
| Faltynek, CR | 1 |
| Krafte, DS | 1 |
| Jarvis, MF | 1 |
| Sharma, M | 1 |
| Dash, SS | 1 |
| Matharasala, G | 1 |
| Deekshith, V | 1 |
| Sriram, D | 1 |
| Yogeeswari, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Nicotinamide Riboside (NR) in Paclitaxel-induced Peripheral Neuropathy[NCT03642990] | Phase 2 | 5 participants (Actual) | Interventional | 2019-11-08 | Terminated (stopped due to Enrollment challenges) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Difference in Score on the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - neurotoxicity questionnaire at the end of treatment; i.e. Score at screening - score at end of treatment. This questionnaire asks 11 questions that are specific to chemotherapy-induced peripheral neuropathies. Maximum score is 44, minimum score is 0. Positive differences indicate a decrease in neuropathy. Negative differences indicate a worsening of neuropathy. Zero means unchanged. (NCT03642990)
Timeframe: 4 weeks
| Intervention | units on a scale (Median) |
|---|---|
| NIAGEN®) | 7 |
Exploratory analysis of ability of the clinical version of the Total Neuropathy Score questionnaire to detect changes in CIPN severity over time. Unlike the CTCAE or the FACT&GOG-NTX questionnaires, the TNS is a patient reported outcome measure. HIghest score (worse neuropathy is 24, lowest score is 0. Outcome assessed difference between end of treatment and screening. A positive number indicates improvement in neuropathy (NCT03642990)
Timeframe: 4 weeks
| Intervention | score on a scale (Median) |
|---|---|
| NIAGEN®) | 2 |
Count the number of (i.e. the incidence) of dose reduction events due to neuropathy (each occasion of dose reduction is a separate event); (NCT03642990)
Timeframe: 3 weeks
| Intervention | event (Number) |
|---|---|
| NIAGEN®) | 0 |
"The primary outcome variable is defined as no worsening of the grade of peripheral sensory neuropathy as scored according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 guidelines. Per the CTCAE a score of 1 would be assigned in the instance of parethesias or a loss of deep tendon reflexes. A score of 2 would be assigned in the instance of moderate symptoms that limit instrumental activities of daily living. A score of 3 would be assigned in the instance of severe symptoms that limit self-care activities of daily living. Because the outcome measure is defined as no worsening of the grade, it was recorded as either yes( i.e. it worsened) or no (i.e. it did not worsen)." (NCT03642990)
Timeframe: approximately 4 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 3 |
Quantitate the percentage of patients that experience a dose reduction of paclitaxel or nab-paclitaxel therapy due to neuropathy. (NCT03642990)
Timeframe: 3 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| NIAGEN®) | 0 |
Paclitaxel levels in plasma were measured ~30 min after each infusion of taxane. This was undertaken to ascertain whether NIAGEN altered plasma levels of paclitaxel because increases or decreases in plasma levels of paclitaxel by itself could lead to an apparent worsening or improvement, respectively, in CIPN and confound interpretation of NIAGEN's effect. (NCT03642990)
Timeframe: up to 3 weeks
| Intervention | ng/ml (Median) |
|---|---|
| NIAGEN®) | 810 |
Quantitate the total cumulative dose of paclitaxel administered over the 12 weeks. (NCT03642990)
Timeframe: 3 weeks
| Intervention | mg/M^2 (Number) |
|---|---|
| NIAGEN®) | 200 |
10 other studies available for niacinamide and Allodynia
| Article | Year |
|---|---|
HDAC6 Inhibition Reverses Cisplatin-Induced Mechanical Hypersensitivity via Tonic Delta Opioid Receptor Signaling.
Topics: Analgesics, Opioid; Animals; Antibodies, Neutralizing; Antineoplastic Agents; Cisplatin; Enkephalin, | 2022 |
Nicotinamide riboside, a form of vitamin B3 and NAD+ precursor, relieves the nociceptive and aversive dimensions of paclitaxel-induced peripheral neuropathy in female rats.
Topics: Animals; Antineoplastic Agents, Phytogenic; Disease Models, Animal; Eosinophils; Escape Reaction; Fe | 2017 |
Antihyperalgesic activity of a mexicanolide isolated from Swietenia humilis extract in nicotinamide-streptozotocin hyperglycemic mice.
Topics: Analgesics; Animals; Diabetes Mellitus, Experimental; Hyperalgesia; Hyperglycemia; Hypoglycemic Agen | 2017 |
Thiamine, riboflavin, and nicotinamide inhibit paclitaxel-induced allodynia by reducing TNF-α and CXCL-1 in dorsal root ganglia and thalamus and activating ATP-sensitive potassium channels.
Topics: Animals; Chemokine CXCL1; Ganglia, Spinal; Hyperalgesia; KATP Channels; Male; Mice; Neuralgia; Niaci | 2020 |
Spinal SIRT1 activation attenuates neuropathic pain in mice.
Topics: Animals; Down-Regulation; Hyperalgesia; Male; Mice; Mice, Inbred Strains; NAD; Neuralgia; Niacinamid | 2014 |
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.
Topics: Analgesics; Analysis of Variance; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Respo | 2015 |
Antinociceptive and hypoglycaemic evaluation of Conyza filaginoides (D.C.) Hieron Asteraceae.
Topics: Analgesics; Animals; Behavior, Animal; Biomarkers; Blood Glucose; Conyza; Diabetes Mellitus, Experim | 2015 |
Functional and biochemical evidence indicating beneficial effect of Melatonin and Nicotinamide alone and in combination in experimental diabetic neuropathy.
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Diabetic Neuropathies; Disease Models, Animal; Do | 2010 |
A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats.
Topics: Animals; Biophysics; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Elec | 2010 |
Novel piperazinyl derivatives with anti-hyperalgesic, anti-allodynic and anti-inflammatory activities useful for the treatment of Neuropathic Pain.
Topics: Animals; Anti-Inflammatory Agents; Female; Hyperalgesia; Male; Mice; Neuralgia; Niacinamide; Piperaz | 2012 |